BLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
TREMFYA (guselkumab) by Johnson & Johnson is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2017.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREMFYA (guselkumab) is a monoclonal antibody developed by Johnson & Johnson that selectively antagonizes interleukin-23 (IL-23), a key cytokine in inflammatory and immune-mediated diseases. Approved by the FDA on July 13, 2017, it is administered via subcutaneous injection. The drug is indicated for treatment of moderate-to-severe plaque psoriasis and other IL-23-driven conditions. It represents a targeted approach to reducing inflammatory signaling in dermatological and systemic diseases.
$0.5BPart D
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab
Started Apr 2026
50 enrolled
Inflammatory Bowel DiseaseColitis, UlcerativeCrohn Disease
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Started Apr 2026
530 enrolled
Crohn Disease
A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
Started Apr 2026
100 enrolled
ColitisUlcerativeCrohn Disease
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Started Apr 2026
88 enrolled
Crohn's Disease (CD)
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Started Apr 2026
200 enrolled
Arthritis, Psoriatic
Worked on TREMFYA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.